Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (JCO)
December 22, 2021 08:30 ET
|
Agenus Inc.
Objective response rate (ORR) of 32.8% in PD-L1-positive patients and 25.6% in all patients regardless of PD-L1 statusBoth ORRs and durability of responses are higher than what has been demonstrated...
Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference
November 17, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to...
Clinical Activity of AGEN1181 Demonstrated Across Nine Treatment-Resistant Cancers at SITC
November 12, 2021 07:00 ET
|
Agenus Inc.
Seventeen objective responses reported across nine cancersEvidence of monotherapy activity, with four cases of confirmed objective responseObjective responses noted in treatment refractory, poorly...
Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
November 09, 2021 08:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to...
Agenus Corporate Update and Third Quarter 2021 Financial Report
November 09, 2021 08:00 ET
|
Agenus Inc.
Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred...
Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
November 04, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
October 25, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Agenus Provides Update on Balstilimab Development
October 22, 2021 08:00 ET
|
Agenus Inc.
Company voluntarily withdraws BLA at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal dateBalstilimab achieved trial endpoints with 20%...
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
October 12, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus to Present AGEN1181 Clinical Data at SITC
October 01, 2021 08:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...